Attovia Therapeutics priced its upsized IPO at $17 per share on August 4, 2026, raising $289 million in gross proceeds at a $731.5 million valuation, reflecting robust investor demand for its ATTOBODY platform targeting immune-mediated conditions. Shares debuted on Nasdaq under ticker ATTO on August 5 and rose sharply in early trading, reaching levels that imply a closing market capitalization near $942 million. This outcome aligns with the market-implied odds of 100% for the $900 million–$1 billion range, driven by the company’s recent Series C financing, clinical-stage pipeline momentum, and favorable biotech IPO sentiment. Scenarios that could still alter the final closing figure include last-minute order flow shifts, broader market volatility affecting small-cap biotechs, or underwriter stabilization activity around the greenshoe option.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日9億ドル～10億ドル 100.0%
6億ドル未満 <1%
6億ドル〜7億ドル <1%
7億ドル〜8億ドル <1%
$1,858 Vol.
$1,858 Vol.
2026/08/05
6億ドル未満
いいえ
6億ドル〜7億ドル
いいえ
7億ドル〜8億ドル
いいえ
8億ドル〜9億ドル
いいえ
9億ドル～10億ドル
はい
10億ドル以上
いいえ
2026年10月以前にIPOなし
いいえ
9億ドル～10億ドル 100.0%
6億ドル未満 <1%
6億ドル〜7億ドル <1%
7億ドル〜8億ドル <1%
$1,858 Vol.
$1,858 Vol.
2026/08/05
6億ドル未満
$163 Vol.
いいえ
6億ドル〜7億ドル
$414 Vol.
いいえ
7億ドル〜8億ドル
$238 Vol.
いいえ
8億ドル〜9億ドル
$50 Vol.
いいえ
9億ドル～10億ドル
$270 Vol.
はい
10億ドル以上
$553 Vol.
いいえ
2026年10月以前にIPOなし
$170 Vol.
いいえ
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Attovia Therapeutics priced its upsized IPO at $17 per share on August 4, 2026, raising $289 million in gross proceeds at a $731.5 million valuation, reflecting robust investor demand for its ATTOBODY platform targeting immune-mediated conditions. Shares debuted on Nasdaq under ticker ATTO on August 5 and rose sharply in early trading, reaching levels that imply a closing market capitalization near $942 million. This outcome aligns with the market-implied odds of 100% for the $900 million–$1 billion range, driven by the company’s recent Series C financing, clinical-stage pipeline momentum, and favorable biotech IPO sentiment. Scenarios that could still alter the final closing figure include last-minute order flow shifts, broader market volatility affecting small-cap biotechs, or underwriter stabilization activity around the greenshoe option.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
マーケット開始日： Aug 4, 2026, 9:51 PM ET
音量
$1,858終了日
2026/08/05マーケット開始日
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...提案された結果: いいえ
異議申し立てなし
最終結果: いいえ
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Attovia Therapeutics priced its upsized IPO at $17 per share on August 4, 2026, raising $289 million in gross proceeds at a $731.5 million valuation, reflecting robust investor demand for its ATTOBODY platform targeting immune-mediated conditions. Shares debuted on Nasdaq under ticker ATTO on August 5 and rose sharply in early trading, reaching levels that imply a closing market capitalization near $942 million. This outcome aligns with the market-implied odds of 100% for the $900 million–$1 billion range, driven by the company’s recent Series C financing, clinical-stage pipeline momentum, and favorable biotech IPO sentiment. Scenarios that could still alter the final closing figure include last-minute order flow shifts, broader market volatility affecting small-cap biotechs, or underwriter stabilization activity around the greenshoe option.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
音量
$1,858終了日
2026/08/05マーケット開始日
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...提案された結果: いいえ
異議申し立てなし
最終結果: いいえ
Attovia Therapeutics priced its upsized IPO at $17 per share on August 4, 2026, raising $289 million in gross proceeds at a $731.5 million valuation, reflecting robust investor demand for its ATTOBODY platform targeting immune-mediated conditions. Shares debuted on Nasdaq under ticker ATTO on August 5 and rose sharply in early trading, reaching levels that imply a closing market capitalization near $942 million. This outcome aligns with the market-implied odds of 100% for the $900 million–$1 billion range, driven by the company’s recent Series C financing, clinical-stage pipeline momentum, and favorable biotech IPO sentiment. Scenarios that could still alter the final closing figure include last-minute order flow shifts, broader market volatility affecting small-cap biotechs, or underwriter stabilization activity around the greenshoe option.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問